# Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder

Source: https://onco.cc/trials/nct07072728/  
OnCo record `nct07072728` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Psilocybin therapy in endometrial cancer, prostate cancer, gastric & gastro-oesophageal junction cancer, melanoma and pancreatic ductal adenocarcinoma, run by Psyence Australia Pty Ltd, now recruiting.

## Summary

Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder is a phase 2 interventional study registered as NCT07072728 by Psyence Australia Pty Ltd, with 87 participants planned, started 2025-10-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: Psilocybin therapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07072728
- Phase: 2
- Setting: A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.
- Sponsor: Psyence Australia Pty Ltd
- Enrolled: 87

## Sources

- ClinicalTrials.gov NCT07072728: https://clinicaltrials.gov/study/NCT07072728

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Melanoma](https://onco.cc/cancers/melanoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct07072728.json